Shield Therapeutics plc (SHIEF)

Market Cap	57.09M -11.4%
Revenue (ttm)	49.70M +54.4%
Net Income	-17.66M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,000
Open	0.0521
Previous Close	0.0580
Day's Range	0.0521 - 0.0558
52-Week Range	0.0521 - 0.1679
Beta	1.72
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Shield Therapeutics

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru (ferric maltol), a non-salt based oral therapy for patients to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, United Kingdom.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2008
• Employees: 61
• Stock Exchange: OTCMKTS
• Ticker Symbol: SHIEF

Financial Performance

In 2025, Shield Therapeutics's revenue was $49.70 million, an increase of 54.45% compared to the previous year's $32.18 million. Losses were -$17.66 million, -35.05% less than in 2024.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 11, 2026

Data Sources Report a data error